Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS
Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica M. Stempel, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Samuel Urrutia, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine McMahon, Rory M. Shallis, Joshua F. Zeidner, Hayley Hawkins, Michael R. Savona, Namrata Sonia Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L. Blood Cancer Journal
· Springer Nature
· 2026-11-14
· DOI: 10.1038/s41408-026-01584-x
Abstract
Blood Cancer Journal, Published online: 14 November 2026; doi:10.1038/s41408-026-01584-x Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS
Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica M. Stempel, Najla H. Al Ali et al. Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS. // Blood Cancer Journal. – 2026. – DOI: 10.1038/s41408-026-01584-x. – URL: https://www.nature.com/articles/s41408-026-01584-x
Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica M. Stempel, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Samuel Urrutia, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine McMahon, Rory M. Shallis, Joshua F. Zeidner, Hayley Hawkins, Michael R. Savona, Namrata Sonia Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, & Maria L (2026). Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS. Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01584-x
Tariq Kewan, et al. “Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS.” Blood Cancer Journal, 2026. doi:10.1038/s41408-026-01584-x.
@article{Kewan2026,
title = {Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS},
author = {Kewan, Tariq and Bewersdorf, Jan Philipp and Lanino, Luca and Blaha, Ondrej and Stempel, Jessica M. and Ali, Najla H. Al and DeZern, Amy E. and Sekeres, Mikkael A. and Uy, Geoffrey L. and Urrutia, Samuel and Carraway, Hetty E. and Desai, Pinkal and Griffiths, Elizabeth A. and Stein, Eytan M. and Brunner, Andrew M. and McMahon, Christine and Shallis, Rory M. and Zeidner, Joshua F. and Hawkins, Hayley and Savona, Michael R. and Chandhok, Namrata Sonia and Logothetis, Constantine and Bidikian, Aram and Getz, Ted M. and Roboz, Gail J. and Rolles, Benjamin and Wang, Eunice S. and Harris, Amyah C. and L., Maria},
journal = {Blood Cancer Journal},
year = {2026},
doi = {10.1038/s41408-026-01584-x},
url = {https://www.nature.com/articles/s41408-026-01584-x}
}